Company news
Rigel Pharmaceuticals, Inc. news in 2022
Rigel Pharmaceuticals, Inc.'s news releases, calls and decks from 2022, newest first.
Rigel Announces Availability of REZLIDHIA™ (olutasidenib) in the U.S. for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation
December 21, 2022
Rigel Doses First Patient in Phase 1b Study of R289 for the Treatment of Lower-Risk Myelodysplastic Syndromes
December 14, 2022
Rigel Announces U.S. FDA Approval of REZLIDHIA™ (olutasidenib) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation
November 30, 2022
Rigel Announces Publication of Early Clinical Data of Olutasidenib in The Lancet Haematology
November 9, 2022
Rigel Reports Third Quarter 2022 Financial Results and Provides Business Update
November 2, 2022
Rigel Announces Five Poster Presentations at the Upcoming 64th American Society of Hematology Annual Meeting and Exposition
November 2, 2022
Rigel Announces Top-line Results from FOCUS Phase 3 Clinical Trial of Fostamatinib in High Risk Hospitalized COVID-19 Patients
October 31, 2022
Rigel Announces Conference Call and Webcast to Report Third Quarter 2022 Financial Results and Business Update
October 26, 2022
Rigel Provides Update on Plans for sNDA for wAIHA Program Following FDA Feedback
October 9, 2022
Rigel Reports Second Quarter 2022 Financial Results and Provides Business Update
August 1, 2022
Rigel Pharmaceuticals and Forma Therapeutics Announce Licensing Agreement for Olutasidenib, a Novel Mutant IDH1 Inhibitor for the Potential Treatment of Relapsed or Refractory Acute Myeloid Leukemia
August 1, 2022
Rigel Announces Conference Call and Webcast to Report Second Quarter 2022 Financial Results and Business Update
July 25, 2022
Rigel Announces Top-line Results from FORWARD Phase 3 Clinical Trial of Fostamatinib in Patients with Warm Autoimmune Hemolytic Anemia
June 7, 2022
Rigel Reports First Quarter 2022 Financial Results and Provides Business Update
May 2, 2022
Rigel Announces Conference Call and Webcast to Report First Quarter 2022 Financial Results and Business Update
April 25, 2022
Rigel Announces Publication of Data from Phase 2 Clinical Study of Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia in the American Journal of Hematology
March 7, 2022
Rigel Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
February 28, 2022
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End 2021 Financial Results and Business Update
February 21, 2022
Calls in 2022
- Rigel Pharmaceuticals (NASDAQ:RIGL) Q3 2022 Earnings Call
Nov 3, 2022
Transcript - Rigel Pharmaceuticals (NASDAQ:RIGL) Q2 2022 Earnings Call
Aug 2, 2022
Transcript - Rigel Pharmaceuticals (NASDAQ:RIGL) Q1 2022 Earnings Call
May 3, 2022
Transcript - Rigel Pharmaceuticals (NASDAQ:RIGL) Q4 2021 Earnings Call
Mar 1, 2022
Transcript